Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of R-112. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK known ✓ | P43405 | 15/20 | 1.00 |
| ▸ | AURKA | O14965 | 4/20 | 0.70 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.70 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.70 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.70 |
| ▸ | KDR | P35968 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| R-112 SCHEMBL31294216 | 1.00 | SYK (1.00) | SYKAURKAMAPK8AURKBCDK19 | |
| R-112 SCHEMBL29360016 | 1.00 | SYK (1.00) | SYKAURKAMAPK8AURKBCDK19 | |
| SCHEMBL656495 | 0.93 | SYK (0.87) | SYKAURKAMAPK8AURKBCDK19 | |
| SCHEMBL657334 | 0.93 | SYK (0.87) | SYKAURKAMAPK8AURKBCDK19 | |
| SCHEMBL12567975 | 0.92 | SYK (0.85) | SYKAURKAMAPK8AURKBCDK19 | |
| SCHEMBL27612598 | 0.92 | SYK (0.85) | SYKAURKAMAPK8AURKBCDK19 | |
| R-112 SCHEMBL2483279 | 0.90 | SYK (0.81) | SYKAURKAMAPK8AURKBCDK19 | |
| SCHEMBL656818 | 0.90 | SYK (0.81) | SYKAURKAMAPK8AURKBCDK19 | |
| SCHEMBL655815 | 0.90 | SYK (0.81) | SYKAURKAMAPK8AURKBCDK19 | |
| SCHEMBL656319 | 0.89 | SYK (0.86) | SYKAURKAMAPK8AURKBCDK19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 400 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240122927-A1 | METHODS FOR TREATING HEMOLYTIC DISEASES AND SICKLE CELL DISEASE | PURDUE RESEARCH FOUNDATION | 2024-04-18 | — | — | US | claimed |
| EP-3191098-A1 | COMBINATIONS AND DOSING REGIMES TO TREAT RB-POSITIVE TUMORS | G1 Therapeutics, Inc. (US) | 2017-07-19 | — | — | EP | claimed |
| WO-2016040858-A1 | COMBINATIONS AND DOSING REGIMES TO TREAT RB-POSITIVE TUMORS | G1 THERAPEUTICS, INC. (US) | 2016-03-17 | — | — | WO | claimed |
| EP-1471915-B1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS INC (US) | 2011-09-14 | — | — | EP | claimed |
| EP-2130541-A2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | Rigel Pharmaceuticals, Inc. (US) | 2009-12-09 | — | — | EP | claimed |
| US-20080039622-A1 | Inhibiting the immunoglobulin (Ig) IgE and/or IgG receptor using R940343, N4-[(2,2-Difluoro-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine; treating allergic and inflammatory diseases; syk kinase inhibitors | RIGEL PHARMACEUTICALS, INC. | 2008-02-14 | — | — | US | claimed |
| US-7329671-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2008-02-12 | — | — | US | claimed |
| US-20080027034-A1 | Ciclesonide and Syk Inhibitor Combination and Method of Use Thereof | NYCOMED GMBH (DE) | 2008-01-31 | — | — | US | claimed |
| EP-1796679-A1 | CICLESONIDE AND SYK INHIBITOR COMBINATION AND METHODS OF USE THEREOF | Altana Pharma AG (DE) | 2007-06-20 | — | — | EP | claimed |
| EP-1791538-A1 | ROFLUMILAST AND SYK INHIBITOR COMBINATION AND METHODS OF USE THEREOF | Altana Pharma AG (DE) | 2007-06-06 | — | — | EP | claimed |
| WO-2006027378-A1 | ROFLUMILAST AND SYK INHIBITOR COMBINATION AND METHODS OF USE THEREOF | ALTANA PHARMA AG (DE) | 2006-03-16 | — | — | WO | claimed |
| US-20060058292-A1 | N4-[2,2-difluoro-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine; inhibit the immunoglobulins IgE or IgG receptor signaling cascades in mast, basophil cells; antiallergen, antiinflammatory agent; asthma, osteoarthritis | MIDCAP FINANCIAL TRUST | 2006-03-16 | — | — | US | claimed |
| WO-2006027377-A1 | CICLESONIDE AND SYK INHIBITOR COMBINATION AND METHODS OF USE THEREOF | ALTANA PHARMA AG (DE) | 2006-03-16 | — | — | WO | claimed |
| US-20060035916-A1 | N2,N4-bis(3-hydroxyphenyl)-5-fluoro-2,4-pyrimidinediamine or a salt, hydrate, solvate and/or N-oxide; inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; Syk kinase inhibitors | MIDCAP FINANCIAL TRUST | 2006-02-16 | — | — | US | claimed |
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| EP-4717317-A2 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2026-04-01 | — | — | EP | disclosed |
| US-12565502-B2 | Substituted 1′,2′-dihydro-3′h-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c] [1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors | PHARMACOSMOS HOLDING A/S (KR) | 2026-03-03 | — | — | US | disclosed |
| EP-1471915-A2 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | Rigel Pharmaceuticals, Inc. (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20040029902-A1 | Antiinflamamtory agents | MIDCAP FINANCIAL TRUST | 2004-02-12 | — | — | US | disclosed |
| WO-2003063794-A2 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027034-A1 | Ciclesonide and Syk Inhibitor Combination and Method of Use Thereof | SYK, ZAP70, BTK | SYK 1/4885AURKA 1484/4885MAPK8 3396/4885 |
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | NEDD4, UBE3A, UBE3C | SYK 4313/4885AURKA 4090/4885MAPK8 3785/4885 |
| US-20060058292-A1 | N4-[2,2-difluoro-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine; inhibit the immunoglobulins IgE or IgG receptor signaling cascades in mast, basophil cells; antiallergen, antiinflammatory agent; asthma, osteoarthritis | FCER2, FCGR1A, HRH4 | SYK 36/4885AURKA 533/4885MAPK8 1076/4885 |
| US-20240122927-A1 | METHODS FOR TREATING HEMOLYTIC DISEASES AND SICKLE CELL DISEASE | SYK, BTK, CD47 | SYK 1/4885AURKA 1226/4885MAPK8 1312/4885 |
| US-20060035916-A1 | N2,N4-bis(3-hydroxyphenyl)-5-fluoro-2,4-pyrimidinediamine or a salt, hydrate, solvate and/or N-oxide; inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; Syk kinase inhibitors | SYK, FCER2, FCGR1A | SYK 1/4885AURKA 928/4885MAPK8 1271/4885 |
| US-20040029902-A1 | Antiinflamamtory agents | FCER2, FCGR1A, HNMT | SYK 251/4885AURKA 1221/4885MAPK8 1522/4885 |
| US-20080039622-A1 | Inhibiting the immunoglobulin (Ig) IgE and/or IgG receptor using R940343, N4-[(2,2-Difluoro-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine; treating allergic and inflammatory diseases; syk kinase inhibitors | FCER2, FCGR1A, FCGR2A | SYK 4/4885AURKA 240/4885MAPK8 2366/4885 |
| US-12565502-B2 | Substituted 1′,2′-dihydro-3′h-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c] [1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors | CCNO, CDK2, CCNI | SYK 1900/4885AURKA 789/4885MAPK8 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.